K Health | $50,000,000 | (Jul 2, 2024)
Vytal | The reuse system | $6,644,850 | (Jul 2, 2024)
Pieces for Developers | $13,500,000 | (Jul 2, 2024) Certified by Founder
Lodge
Kate Therapeutics
start up
United States
- San Diego, California
- 08/06/2023
- Series A
- $51,000,000
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.
- Industry Biotechnology Research
- Website https://www.katetherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kate-therapeutics/
N-Power Medicine, Inc. | Undisclosed Amount | (Jul 2, 2024)
Waypoint Bio | $14,500,000 | (Jul 2, 2024)
Supercede | The Reinsurance Platform | $15,000,000 | (Jun 28, 2024)
Smartworks | $12,000,000 | (Jun 28, 2024)
Synthflow AI | $7,400,000 | (Jun 28, 2024)
Odaseva | $54,000,000 | (Jun 28, 2024)
KarmaCheck | $45,000,000 | (Jun 28, 2024)
Dodona Analytics | Undisclosed Amount | (Jun 28, 2024)